When it comes to the opioid epidemic, many have turned to new remedies such as kratom for help. Now, President Trump’s former drug czar has come forward to address the complexity of this substance, and what federal officials have been doing behind the scenes. In a recent expose, the former czar has divulged the truth regarding the scheduling of kratom by the Food and Drug Administration (FDA), and why it has yet to happen.
1. Trump Drug Czar Cites Top Officials’ Interference with FDA’s Kratom Scheduling
President Donald Trump’s drug czar James W. Carroll has spoken up about the complications and interference being caused by certain top officials at the U.S. Food and Drug Administration with regards to the scheduling of Kratom. According to Carroll, certain top officials at the FDA are interfering with reviews of the Kratom case.
This is a troubling sign as it suggests that certain top officials may be undermining the work of the FDA and their efforts to mitigate the potential risks associated with Kratom use. Furthermore, there are even some FDA officials that have expressed concerns regarding the scheduling of the drug.
- Caroll voiced his concern with regards to Kratom scheduling reviews.
- Certain top officials at the FDA may be undermining the work of the agency.
- Even some within the FDA have expressed their own concerns over the scheduling.
The FDA’s decision to interfere with the Kratom scheduling process is a concern that needs to be addressed before any decisions on its eventual placement are made. Carroll is not the only one raising an eyebrow at this flurry of activity. Many legal experts and professionals have also echoed his sentiments. It is imperative that any interference from top officials be looked into before the Kratom scheduling process is finalized.
2. Puzzling Suppression of Kratom Scheduling by Federal Powers
Kratom, a Southeast Asian plant with medicinal and recreational potential, has been a topic of much dispute in recent years, particularly when it comes to the regulation of it by federal powers. Individuals, scientists, and communities have been voicing their concerns with kratom’s back and forth scheduling, with hopes that it can serve its primary purpose of aiding health and well-being.
The Federal authority’s response to the CBD scheduling debate has been mysterious. For example, the Drug Enforcement Administration (DEA) launched an emergency labeling classification for Kratom in 2016, deeming it a Schedule I drug with no medical value. Soon after, the DEA immediately abandoned the plan, claiming that the “public and congressional response to DEA’s intention to place Kratom temporarily into Schedule I of the Controlled Substances Act triggered an intense and broad-based response”.
- In the US, Kratom is not currently a controlled substance
- The DEA’s 2016 plan to classify Kratom has since been abandoned
- The federal authority’s response to Kratom scheduling has been particularly mysterious
3. Kratom Debate Heats Up as Former Czar Points to ‘Bias’
The kratom debate has been escalating in recent weeks following comments from the former Czar on the subject. During a recent debate, he accused the media of having a “biased” approach to their coverage on the controversial subject. Since then, both sides of the issue have been fighting to have their voice heard.
The most vocal opponent to the legalization of kratom is the public health sector. They view it as a potential danger to public health, going so far as to suggest drugs which are “closely related” to it, such as opioids and illegal drugs, should also be banned. Proponents of the substance take a different stance, claiming it has a wide range of applications in the medical and recreational fields, and can be beneficial if used in moderation.
- People in favor of kratom point to its various applications in the medical field.
- People opposed to it claim it could pose a danger to public health.
4. Impact of Top Officials’ Kratom Decisions Remains Unclear
The officials’ decisions to criminalize or legalize kratom has had major implications for the kratom industry and community. On the one hand, officials have caused certain kratom products to become significantly more expensive, reducing their availability for some users. At the same time, criminalization or legalization of kratom has the potential to bring about a boost in public awareness, which could help spur research and innovation.
However, the true impact of the decisions made by top officials related to kratom remains unclear. There could be numerous beneficial or detrimental effects to criminalizing or legalizing kratom, depending on the region. Some of these unknown implications could include:
- Increase in taxes on kratom manufacturers and retailers in legalized regions
- Reduction in funding for research in criminalized regions
- Reduction in user health and safety through access to unregulated kratom in some regions
- Reduction in potential exports of kratom in criminalized regions
We can only hope that officials will heed the potential positive and negative effects of their decisions, and make a balanced decision that considers the safety and well-being of people as well as the financial health of the kratom industry.
At best, the former US drug czar’s allegations suggest a troubling lack of transparency about the federal government’s decision-making process when it comes to scheduling drugs and substances. At worst, they suggest a potential cover-up of potential concerns relating to perceived FDA bias. Whatever the truth may be, one thing is certain: the decision to schedule drugs has real implications for people’s lives, and it is crucial that the public knows exactly how and why those decisions are being made.